Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 at a level of 1 or ...
This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.
The expansion arm will assess the safety, optimal dosing, and early anti-tumor activity of Decoy20 in combination with tislelizumab. Initial participants will receive a week of Decoy20 monotherapy ...
Key findings support weekly induction of immune cell trafficking by Decoy20, a critical factor in effective cancer immunotherapyNEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc.
South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug ...
Given the patient’s favorable initial tumor response and strong request, immunotherapy was cautiously reinstated using tislelizumab after thorough clinical evaluation. Following four cycles of ...
Looking for a comprehensive and reliable source of stock market news? Benzinga creates actionable, market-moving stock news content that is all written in-house. Benzinga’s editorial team cuts ...
TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected metastasis or suspected recurrence. The FDA approved TLX007-CDx, a kit for preparing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback